Results for this period
Interim period (second quarter)1 October 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company received advance payments associated with an order for HGF drug substance from クラリス・バイオセラピューティクス and recognized a technology access fee (royalty income) as revenue. As a result of conducting research and development activities and other operations, the operating loss widened from the same period of the previous year.
Events or conditions that may cast significant doubt are disclosed. The company faces conditions that may raise significant doubt, including recurring operating losses, negative cash flow from operating activities, and delays in regulatory filings. However, it has determined that there is no material uncertainty regarding the going-concern assumption at this time. No matters requiring disclosure in the going-concern note apply.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥36 million (YoY +2.2%) |
| Operating profit | ¥-515 million |
| Ordinary income | ¥-513 million |
| Profit attributable to owners of the parent | ¥-516 million |
| Net income per share | △71.37 |
| Equity ratio | End of the current fiscal period 45.9 / End of previous period 61.5 |
| Total assets | ¥1,988 million |
| Net assets | ¥947 million |
| Cash flows from operating activities | ¥-169,218 thousand |
| Cash flows from investing activities | ¥-2,181 thousand |
| Cash flows from financing activities | ¥140,586 thousand |
| Cash and cash equivalents at end of period | ¥960,483 thousand |
| Full-year earnings forecast | Net Sales ¥332 million (YoY +360.4%) / Operating profit ¥-1,018 million / Ordinary income ¥-1,018 million / Net income ¥-1,020 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Impairment Losses on Shares of Affiliates / Amount ¥1,797 thousand |
| Disclosure regarding the going concern assumption | Events or conditions that may cast significant doubt are disclosed. The company faces conditions that may raise significant doubt, including recurring operating losses, negative cash flow from operating activities, and delays in regulatory filings. However, it has determined that there is no material uncertainty regarding the going-concern assumption at this time. No matters requiring disclosure in the going-concern note apply. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | From 1 April to 11 May 2026, 6,830 of the 16th series of stock acquisition rights were exercised, resulting in the issuance of 683,000 common shares and proceeds of ¥284,128 thousand. Capital stock and capital reserve each increased by ¥142,265 thousand. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (対象者：Not disclosed) |
| Issued Shares at Period-End | 7,395,200 |
| Treasury Shares at Period-End | 183 |
| Factors Behind Changes in Business Performance | The company received advance payments associated with an order for HGF drug substance from クラリス・バイオセラピューティクス and recognized a technology access fee (royalty income) as revenue. As a result of conducting research and development activities and other operations, the operating loss widened from the same period of the previous year. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following an order for HGF drug substance from クラリス・バイオセラピューティクス, the company recognized a technology access fee (royalty income) as revenue.